Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
Science communication brings behavioural changes
Tavaborole Topical Solution, 5% had annual sales of US $3.1 million in the United States
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Azithromycin Tablets USP, 500 mg had annual sales of US $20 million in the United States
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
To enable company to be future-ready by tapping potential in CDMO space
MoU signed between AIIA and University of Amrita Vishwa Vidhyapeetham for collaboration in the field of Research and Academics in Ayurveda
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
Subscribe To Our Newsletter & Stay Updated
